Global Pain Therapeutics Market to 2023 - Innovative New Products to Address Unmet Need within Chronic Pain and Migraine, and Tackle Opioid Abuse
Global Pain Therapeutics Market to 2023 - Innovative New Products to Address Unmet Need within Chronic Pain and Migraine, and Tackle Opioid Abuse

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document.

**We look forward to being of service to you.**

*If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.*

**Phone:** +44 (0)7887 945155 **Email:** pdb@bioportfolio.co.uk
Global Pain Therapeutics Market to 2023 - Innovative New Products to Address Unmet Need within Chronic Pain and Migraine, and Tackle Opioid Abuse

Summary

The pain therapeutics market covers the drugs used for the relief of acute and chronic pain. This market has long been characterized by high levels of generic revenue, derived largely from opioids, which see high levels of usage worldwide and particularly within the US.

However, the last decade has seen the addition of new premium products to the market, including a wave of drugs approved for the treatment of neuropathic pain conditions - a patient population that previously had very poor treatment options. This influx of premium products is forecast to continue through to 2023.

The causes of the resurgence of premium analgesics are multi-faceted, but the primary driver is to meet the many unmet needs of the market, such as the treatment of neuropathic pain and migraines, and the need to limit the risk of abuse associated with many analgesics, primarily opioids. The revived interest in this market has led to a very high frequency of licensing deals for pain products over the past decade.

Scope

- The pain therapeutics market is forecast to reach $28.8 billion in 2023. What are the key market segments driving this growth?
- The pipeline contains over 800 products. What molecule types and molecular targets are in the pipeline? What are the commercial prospects of promising late stage products?
- Despite historical high levels of generic drug development, there is a very high proportion of novel drugs in the pipeline. How do failure rates, clinical trial size and clinical trial duration differ by indication and molecular target?
- Which of the leading companies will have the highest market share by 2023? Which new companies will enter the market?
- What licensing and co-development deals have occurred within this therapy area since 2006?

Reasons to buy

- Understand the current clinical and commercial landscape through a comprehensive analysis of innovation in the pain therapeutics market, in the context of the overall pipeline and current market landscape. The report also includes analysis of the deals landscape, including both licensing deals and co-development deals. Key indications covered in detail include neuropathic pain, inflammatory pain (including osteoarthritis pain) and migraine.
- Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.

- Analyse the pain therapeutics pipeline through a comprehensive review, segmented by stage of development, molecule type and molecular target. This review also provides a detailed look at pain therapeutics clinical trials, to provide an insight into the risk associated with attempting to bring pipeline analgesics to market.

- Predict growth in market size, with in-depth market forecasting from 2016 to 2023. The forecast will provide an understanding of how epidemiology trends, new drug entries and new drug patent expirations will influence market value.

- Identify the key pipeline products, with a particular focus on those due to be brought to market in the near future, as well as sales forecasts for these products.

- Identify the leading companies in the market, in terms of market share and growth. Company analysis determines how dependent the key companies in the market are on revenue derived from pain therapeutic products. In addition, analysis determines the primary factors that will drive market growth for the key companies in the market.

- Assess the licensing and co-development deal landscape for pain therapies.

Additional Details

Publisher: GBI Research
Reference:
Number of Pages: 147
Report Format: PDF
Publisher Information:
Table Of Contents for Global Pain Therapeutics Market to 2023 - Innovative New Products to Address Unmet Need within Chronic Pain and Migraine, and Tackle Opioid Abuse [Report Updated: 01-06-2017]

- 1 Table of Contents
- 1.1 List of Tables
- 1.2 List of Figures
- 2 Introduction
  - 2.1 Disease Cluster Introduction
  - 2.2 Symptoms
    - 2.2.1 Migraine
    - 2.2.2 Inflammatory pain and neuropathic pain
  - 2.3 Diagnosis
  - 2.4 Pathophysiology
    - 2.4.1 Nociceptive pain transmission
    - 2.4.2 Pain modulation in the brain
    - 2.4.3 Inflammatory pain
    - 2.4.4 Migraine
    - 2.4.5 Neuropathic pain
  - 2.5 Epidemiology
    - 2.5.1 Migraine
    - 2.5.2 Inflammatory pain
    - 2.5.3 Neuropathic pain
  - 2.6 Comorbidities and Complications
  - 2.7 Treatment
    - 2.7.1 Non-steroidal anti-inflammatory drugs
    - 2.7.2 Opioid medications
    - 2.7.3 Triptans
    - 2.7.4 Other medications
    - 2.7.5 Conclusion
- 3 Key Marketed Products
  - 3.1 Celebrex (celecoxib) - Pfizer
  - 3.2 Nucynta (tapentadol) - Depomed
  - 3.3 Lyrica (pregabalin) - Pfizer
  - 3.4 Exparel (bupivacaine) - Pacira
  - 3.5 Voltaren (diclofenac sodium) - Novartis
  - 3.6 Pennsaid (diclofenac sodium) - Horizon
  - 3.7 Depakine (valproate sodium) - Daiichi Sankyo
  - 3.8 Embeda ER (morphine sulfate + naltrexone) - Pfizer
  - 3.9 Cymbalta (duloxetine hydrochloride) - Eli Lilly
  - 3.10 Conclusion
- 4 Pipeline Landscape Assessment
  - 4.1 Overview
  - 4.2 Pipeline Development Landscape
  - 4.3 Molecular Targets in the Pipeline
  - 4.4 Clinical Trial Landscape
    - 4.4.1 Failure Rate by Stage of Development, Indication and Molecule Type
    - 4.4.2 Clinical Trial Duration by Stage of Development, Indication, and Molecule Type
    - 4.4.3 Clinical Trial Size by Stage of Development, Indication and Molecule Type
    - 4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication and Molecule Type
  - 4.5 Conclusion
  - 4.6 Assessment of Key Pipeline Products
    - 4.6.1 HTX-011 - Heron
    - 4.6.2 Difelikefalin - Cara
    - 4.6.3 Fremanezumab - Teva
    - 4.6.4 Eptinezumab - Alder
    - 4.6.5 Erenumab - Amgen and Novartis
    - 4.6.6 Galcanezumab - Eli Lilly
    - 4.6.7 Zilretta - Flexion
    - 4.6.8 EMA-401 - Novartis
  - 4.6.9 Conclusion
- 5 Multi-scenario Market Forecast to 2022
  - 5.1 Overall Market Size
  - 5.2 Generic Penetration
    - 5.2.1 Generic Opioid Usage
  - 5.3 Revenue Forecast by Molecular Target
    - 5.3.1 Opioid Receptors
    - 5.3.2 Serotonin Receptors 1B and 1D
    - 5.3.3 Prostaglandin G/H Synthase (COX)
    - 5.3.4 Calcitonin Gene Related Peptide Receptors
    - 5.3.5 Multiple Targets
    - 5.3.6 Ion Channels
- 6 Company Analysis and Positioning
  - 6.1 Revenue and Market Share Analysis by Company
    - 6.1.1 Teva - Company Set to Enter the Market and Secure Large Market Share by 2023
    - 6.1.2 Pfizer - Key Patent Expiries to Drive Negative Growth
    - 6.1.3 Pacira - Company to Secure a Large Market Share despite Small Product Portfolio
    - 876.1.4 Novartis - Expansion of Pain Therapeutics Portfolio for the First Time since Voltaren
    - 876.1.5 Amgen - Company Set to Enter Pain Market in Early Forecast Period and Achieve Rapid Growth
    - 869.1.6 Allergan - Expansion of Product Portfolio to Drive Growth
    - 869.1.7 Depomed - Revenue to Rise despite Upcoming Patent Cliff
    - 916.1.8 Lilly - Lilly to Expand Position in Market as Patent for Cymbalta Expires
    - 926.2 Company Landscape
    - 936.3 Marketed and Pipeline Portfolio Analysis
        - 947 Strategic Consolidations
        - 977.1 Licensing Deals
        - 977.1.1 Deals by Region, Value and Year
        - 977.1.2 Deals by Indication
        - 977.1.3 Deals by Stage of Development and Value
        - 977.1.4 Deals by Molecule Type, Molecular Target and Value
        - 1007.1.5 Licensing Deals with Disclosed Values
        - 1017.2 Co-development Deals
        - 1037.2.1 Deals by Region, Value and Year
        - 1037.2.2 Deals by Indication
        - 1047.2.3 Deals by Stage of Development and Value
        - 1047.2.4 Deals by Molecule Type and Value
        - 1057.2.5 Co-development Deal with Disclosed Values
        - 1068 Appendix
        - 1078.1 References
        - 1078.2 List of Pipeline Products
    - 1108.3 Table of Epidemiology Forecast
    - 1428.4 Abbreviations
    - 1448.5 Methodology
    - 1458.5.1 Coverage
    - 1458.5.2 Secondary Research
    - 1458.5.3 Market Size and Revenue Forecasts
    - 1468.5.4 Pipeline Analysis
    - 1468.5.5 Competitive Landscape
- 8 Appendix
  - 8.1 References
  - 8.2 List of Pipeline Products
  - 8.3 Table of Epidemiology Forecast
  - 8.4 Abbreviations
  - 8.5 Methodology
    - 8.5.1 Coverage
    - 8.5.2 Secondary Research
    - 8.5.3 Market Size and Revenue Forecasts
    - 8.5.4 Pipeline Analysis
    - 8.5.5 Competitive Landscape
  - 8.6 Contact Us
  - 8.7 Disclaimer
List Of Tables in Global Pain Therapeutics Market to 2023 - Innovative New Products to Address Unmet Need within Chronic Pain and Migraine, and Tackle Opioid Abuse [Report Updated: 01-06-2017]

1.1 List of Tables

Table 1: Pain Therapeutics Market, Global, Approved Indications for Celebrex, 2017 23
Table 2: Pain Therapeutics Market, Global, Approved Indications for Nucynta, 2017 24
Table 3: Pain Therapeutics Market, Global, Approved Indications for Lyrica, 2017 26
Table 4: Pain Therapeutics Market, Global, Approved Indications for Exparel, 2017 27
Table 5: Pain Therapeutics Market, Global, Approved Indications for Voltaren, 2017 28
Table 6: Pain Therapeutics Market, Global, Approved Indications for Pennsaid, 2017 29
Table 7: Pain Therapeutics Market, Global, Approved Indications for Depakine, 2017 30
Table 8: Pain Therapeutics Market, Global, Approved Indications for Embeda ER, 2017 31
Table 9: Pain Therapeutics Market, Global, Approved Indications for Cymbalta, 2017 33
Table 10: Pain Therapeutics Market, Global, Usage of Generics Across Key Indications, 2016 68
Table 11: Pain Therapeutics Market, Global, Forecast Revenues by Company, 2016-2023 82
Table 12: Pain Therapeutics Market, Global, Pipeline Products, Discovery, 2017 110
Table 13: Pain Therapeutics Market, Global, Pipeline Products, Preclinical, 2017 115
Table 14: Pain Therapeutics Market, Global, Pipeline Products, IND/CTA-filed, 2017 131
Table 15: Pain Therapeutics Market, Global, Pipeline Products, Phase I, 2017 131
Table 16: Pain Therapeutics Market, Global, Pipeline Products, Phase II, 2017 135
Table 17: Pain Therapeutics Market 138
Table 18: Pain Therapeutics Market, Global, Pipeline Products, Pre-registration, 2017 141
Table 19: Pain Therapeutics Market, Global, Pipeline Products, Unknown, 2017 141
Table 20: Pain therapeutics Market, Epidemiology Patterns for Migraine, 2016-2023 142
Table 21: Pain therapeutics Market, Epidemiology Patterns for Post-Herpetic Neuralgia, 2016-2023 143
Table 22: Pain therapeutics Market, Epidemiology Patterns for Trigeminal Neuralgia, 2016-2023 143
Table 23: Abbreviations 144
1.2 List of Figures

Figure 1: Pain Therapeutics Market, Global, Epidemiology Patterns for Migraine, 2016-2023 15
Figure 2: Pain Therapeutics Market, Global, Epidemiology Patterns for Post-Herpetic Neuralgia, 2016-2023 16
Figure 3: Pain Therapeutics Market, Global, Annual Revenue for Nucynta ($m), 2015-2023 25
Figure 4: Pain Therapeutics Market, Global, Annual Revenue for Lyrica ($bn), 2006-2023 27
Figure 5: Pain Therapeutics Market, Global, Annual Revenue for Voltaren ($m), 2006-2023 29
Figure 6: Pain Therapeutics Market, Global, Annual Revenue for Pennsaid ($m), 2015-2023 30
Figure 7: Pain Therapeutics Market, Global, Annual Revenue for Depakine ($m), 2006-2023 31
Figure 8: Pain Therapeutics Market, Global, Annual Revenue for Embeda ER ($m), 2016-2023 32
Figure 9: Pain Therapeutics Market, Global, Annual Revenue for Cymbalta ($bn), 2006-2023 33
Figure 10: Pain Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2017 35
Figure 11: Pain Therapeutics Market, Global, Pipeline by Stage of Development, Molecule Type and Program Type, 2017 36
Figure 12: Pain Therapeutics Market, Global, Pipeline, Key Indications by Stage of Development, 2017 37
Figure 13: Pain Therapeutics Market, Global, Pipeline, Key Indications by Molecule Type, 2017 38
Figure 14: Pain Therapeutics Market, Global, Overall Pipeline by Molecular Target, 2017 40
Figure 15: Pain Therapeutics Market, Global, Pipeline, Key Indications by Molecular Target, 2017 41
Figure 16: Pain Therapeutics Market, Global, Pipeline for Key Indications by Molecular Target, 2017 42
Figure 17: Pain Therapeutics Market, Global, Clinical Trial Failure Rates by Stage of Development and Indication (%), 2006-2017 44
Figure 18: Pain Therapeutics Market, Global, Clinical Trial Failure Rates by Stage of Development and Molecular Target (%), 2006-2017 45
Figure 19: Pain Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2017 46
Figure 20: Pain Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2017 47
Figure 21: Pain Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2017 48
How to Buy...

Global Pain Therapeutics Market to 2023 - Innovative New Products to Address Unmet Need within Chronic Pain and Migraine, and Tackle Opioid Abuse [Report Updated: 01-06-2017]

Option 1 - Online
Go to our website and pay online with any major debit or credit card:
https://www.bioportfolio.co.uk/product/100095

Option 2 - Request a Proforma Invoice
Fill in the details below, and either Scan this page and email it to us at pdb@bioportfolio.co.uk or Fax it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name: .................................................................
Job Title: ......................................................................
Your Email: ..................................................................
Your Contact Phone: ....................................................
Company Name: ............................................................
Address: ........................................................................
Post/Zip Code: ..............................................................
Country: ........................................................................
P.O. Number: ............................................................... Any Other Instructions: ..........................................................

Pricing Options: (please tick one)
○ £4995 | Single User Price
○ £9990 | Site License Price
○ £14985 | Enterprise License Price

Payment Options: (please tick one)
○ Online Credit Card (we will email you the invoice with a payment link)
○ Direct Wire Transfer (we will email you the invoice with our bank details)

Authorising Signature: ..............................................................................................................................

Option 3 - Phone Us on +44 (0)7887 945155
We will be delighted to give you our personal attention.